Paulien Ravenstijn is senior consultant, qPharmetra LLC.

Paulien Ravenstijn 

Extrapolating data from adult clinical trials to a pediatric population is a proven method to avoid unnecessary pediatric clinical trials. Representatives of the Pediatric Working Group of the IQ Consortium share case studies that demonstrate how adult clinical trial data can be used to support the dose selection and regimen—or waive the need for a placebo control arm—for pediatric studies.

Pharmaceutical Technology's Regulatory Sourcebook 

Sebastian Haertter*, sebastian.haertter@boehringer-ingelheim.com, is clinical pharmacology expert (director) translational medicine and clinical pharmacology, Boehringer Ingelheim; S. Y. Amy Cheung is senior director, Certara; Angela James is director, Astellas Pharma Global Development;Ashley Strougo is head of M&S Germany,pharmacokinetics, dynamics and metabolism, translational medicine, Sanofi; Christina Bucci-Rechtweg is global head, pediatric and maternal health policy, Novartis Pharmaceuticals Corporation; Jing Liu is senior director, clinical pharmacology, Pfizer; Meina Tao Tang is principal scientist, clinical pharmacology,Genentech, Inc.; Paulien Ravenstijn is senior consultant, qPharmetra LLC; Raafat Bishai is global clinical program lead, AstraZeneca; Satyendra Suryawanshi is director, clinical pharmacology and pharmacometrics, Bristol Myers Squibb; and Solange Corriol-Rohou is senior regulatory affairs and policy director for Europe, CMO office and chair of AZ Paediatric Work Group Regulatory Excellence, AstraZeneca; all authors are members of the IQ Consortium.

*To whom all correspondence should be addressed.


eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 42–46

When referring to this article, please cite it as Sebastian Haertter et al., “Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development,"

 Pharmaceutical Technology Regulatory Sourcebook eBook 

Paulien Ravenstijn

Articles